Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. This appears to be a version control update with no visible changes to study information or page layout.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. This appears to be a minor technical update without changes to the study content or user-facing features.SummaryDifference0.0%

- Check32 days agoChange DetectedAdded a Show glossary option and updated the page revision to v3.4.0. Capitalization and wording were updated for 'No FEAR Act Data' and 'Last Update Submitted that Met QC Criteria' (replacing the previous 'Last Update Submitted that met QC Criteria').SummaryDifference0.1%

- Check39 days agoChange DetectedRevision label on the page changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedThe Locations section now lists numerous participating sites across the United States, Canada, Australia, and various European and Asian countries.SummaryDifference5%

- Check89 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 appears on the page. This seems to be a minor site version update with no visible changes to study content or user-facing elements.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.